Published on 23/12/2025

One Health considerations in regulatory dossiers

The integration of One Health principles into regulatory submissions for veterinary products is increasingly critical in both the EU and US. This step-by-step tutorial will guide you through the processes involved in ensuring that your regulatory dossiers adequately address zoonotic risks and adheres to guidelines set forth by the FDA, EMA, and other regulatory authorities. The focus extends to zoonotic risk assessment regulatory consulting services aimed at enhancing the safety and efficacy of veterinary products.

Understanding One Health and its Regulatory Implications

The One Health approach recognizes the interconnectedness of humans, animals, and the environment. This philosophy underpins the necessity for a collaborative effort among various disciplines to achieve optimal health outcomes. Zoonoses, diseases that can be transmitted between animals and humans, exemplify the importance of considering human-animal-environmental interactions in risk assessments.

In the context of veterinary regulatory submissions, regulatory bodies such as the FDA’s Center for Veterinary Medicine (CVM) and EMA necessitate that dossier submissions include comprehensive assessments of zoonotic risks associated with veterinary products. This guide outlines the key components you should include when structuring your submissions to comply with these expectations.

Step 1: Compile Comprehensive Scientific Data

The first step in preparing a regulatory dossier focused on One Health considerations is compiling thorough and relevant scientific data. This should cover:

• Pathogen characterization: Detailed profiles of pathogens associated with the target species, including transmission routes and virulence.
• Animal model studies: Results from studies assessing zoonotic transmission in various animal models.
• Epidemiological data: Statistics on prevalent zoonoses, including disease incidence and related human health impacts.

Data collection should align with the guidelines from reputable sources such as the FDA CVM for submissions in the United States and EMA for those in the European Union. Documenting the context and justification of the studies performed solidifies the scientific rigor of your submission.

Step 2: Assess Zoonotic Risks

Once you have compiled the requisite data, the next critical stage is conducting a systematic zoonotic risk assessment. This involves:

• Identifying potential zoonotic agents: Rationalize the zoonotic potential of the active ingredients and formulations.
• Evaluating exposure pathways: Analyze routes of transmission from the animal to humans and assess factors that may exacerbate or mitigate these risks.
• Risk characterization: Quantitatively assess the risks posed by these agents, including the likelihood of transmission and consequences to human health.

This evaluation should conform to established methodologies in areas such as toxicology and epidemiology to ensure its robustness. Incorporating insights from veterinary and public health authorities is critical, as it aligns the assessment with current best practices.

Step 3: Develop a Risk Management Strategy

Following the risk assessment, developers must outline an appropriate risk management strategy, integrating practices that mitigate identified risks. This may include:

• Labeling considerations: Clear indication of any potential zoonotic risks on product labeling.
• Action plans for outbreak management: Strategies to manage zoonotic disease outbreaks in livestock, including surveillance and response protocols.
• Education and training: Ensuring users (veterinarians, farmers) receive proper training regarding the zoonotic risks associated with the veterinary product.

Engagement with stakeholders, including veterinarians, farmers, and public health officials, during this process can provide valuable insights and foster a collaborative environment for risk management.

Step 4: Include Environmental Impact Assessments

One Health considerations also extend to environmental impacts. You must include environmental risk assessments that evaluate how the veterinary product may affect ecosystems. This entails:

• Assessing environmental exposure: Evaluate how residues from the veterinary product might enter the environment, including water sources, soil, and non-target species.
• Modeling ecological risk: Utilize ecological models to predict potential impacts on wildlife and plant species.
• Regulatory compliance: Ensure adherence to environmental regulations, such as those enforced by the EMA and applicable UK legislation.

Collaboration with environmental scientists or ecotoxicologists can enhance the quality of your environmental impact assessment, ensuring that it meets requisite standards.

Step 5: Engage with Regulatory Bodies Early

Engagement with regulatory authorities during the submission process can significantly influence success. Proactively reaching out to FDA CVM or EMA can yield insights that could refine your submission. This could involve:

• Pre-submission meetings: Discussing anticipated challenges or specific data requirements with regulatory agencies.
• Consultations with experts: Utilizing zoonotic risk assessment regulatory consulting services can provide expert guidance tailored to your veterinary product.
• Incorporating feedback: Stay flexible and receptive to feedback from regulators to adapt your scientific data and assessments as necessary.

Such engagements foster transparency and can potentially expedite the review and approval process while motivating adherence to regulatory standards.

Step 6: Compile and Submit Your Dossier

With comprehensive data, risk assessments, management strategies, and stakeholder engagement completed, you are ready to compile your regulatory dossier. Ensure that:

• Structure: Follow the recommended submission structure provided by FDA and EMA, ensuring that all required sections are completed.
• References: Include citations for all data sources, supporting studies, and regulatory references to enhance credibility.
• Review processes: Implement a multi-layered review process to verify the accuracy and completeness of the dossier prior to submission.

Once compiled, follow the regulatory submission procedures specific to your jurisdiction, ensuring compliance with all guidelines stipulated by the FDA CVM or EMA.

Step 7: Post-Submission Monitoring and Pharmacovigilance

Submission of the dossier marks only the beginning of the journey. Post-marketing surveillance and pharmacovigilance are critical steps to ensure continued safety and efficacy. Regulatory authorities require ongoing monitoring for:

• Adverse events: Reporting and analyzing any adverse events associated with veterinary products.
• Emerging zoonotic risks: Maintaining vigilance on new zoonotic trends and assessing how they impact the risk profile of your product.
• Feedback mechanisms: Establishing ways in which stakeholders can provide feedback, enabling a proactive approach to risk management.

This ongoing commitment to monitoring reflects adherence to One Health principles, fostering collaboration among stakeholders to mitigate potential zoonotic risks effectively.

Conclusion

In conclusion, navigating the complexities of regulatory submissions for veterinary products with a One Health perspective requires a systematic and multidisciplinary approach. From thorough scientific data collection to proactive engagement with regulatory bodies, every step plays a crucial role in addressing zoonotic risks effectively. By utilizing zoonotic risk assessment regulatory consulting services, you can leverage expertise and insights that will support your regulatory submissions in both the US and EU. Adhering to this comprehensive framework will not only bolster the safety of veterinary products but also enhance public health outcomes across the One Health continuum.